Anti-TrkB

BDNF/NT-3 growth factors receptor (UniProt: Q16620; also known as EC:2.7.10.1, GP145-TrkB, Trk-B, Neurotrophic tyrosine kinase receptor type 2, TrkB tyrosine kinase, Tropomyosin-related kinase B) is encoded by the NTRK2 (also known as TRKB) gene (Gene ID: 4915) in human. TrkB is a single-pass type I membrane protein that is internalized to endosomes upon ligand-binding. It is synthesized with a signal peptide (aa 1-31) that is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 32-430), a transmembrane domain (aa 431-454), and a cytoplasmic domain (aa 455-822). TrkB is a receptor tyrosine kinase that is involved in the development and maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. In the central nervous system, its expression is observed in the cerebral cortex, hippocampus, thalamus, choroid plexus, granular layer of the cerebellum, brain stem, and spinal cord. In the peripheral nervous system, it is expressed in many cranial ganglia, the ophthalmic nerve, the vestibula, and multiple facial structures. Upon ligand-binding, it undergoes homodimerization, autophosphorylation, and activation. It can then recruit, phosphorylate and/or activate several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. TrkB is also reported to play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia. Following binding of BDNF to TrkB receptor, Tyrosine 816 is phosphorylated, which allows the binding of phospholipase C gamma and activation of signaling cascade.

This rabbit polyclonal antibody detects TrkB (BDNF/NT-3 growth factors receptor). It targets an epitope within 18 amino acids from the C-terminal half, comprising mostly of the extracellular domain.

KLH-conjugated linear peptide corresponding to 18 amino acids from the C-terminal half of human TrkB (BDNF/NT-3 growth factors receptor).

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected TrkB in human hippocampus membrane preparations.

Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution from a representative lot detected TrkB in human cerebral cortex tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Stable for 1 year at +2°C to +8°C from date of receipt.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.